A firm clinical diagnosis of Brugada syndrome and/or sodium channel disease, as indicated by:
1. Spontaneous type 1 (“coved-type”) ST-segment elevation (characterized by ST-segment elevation ≥2 mm (0.2 mV) in ≥1 right precordial leads (V1–V3) positioned in the 4th, 3rd, or 2nd intercostal space),
OR
2. Type 1 ST-segment elevation unmasked using a sodium channel blocker, AND 1 of the following:
a. Documented VF or polymorphic VT, OR
b. Syncope of probable arrhythmic cause, OR
c. A family history of sudden cardiac death at <45 years old with negative autopsy, OR d. A coved-type ECGs in family members, OR e. Nocturnal agonal respiration OR f. Premature atrial arrhythmias at age <30 years 3. Suspicion of sodium channel disease including atrial arrhythmias, sinus node dysfunction, conduction disease and/or QT prolongation, predominantly in children and young people. NOTE: Clinical evaluation in young probands and cascade testing in families will incorporate assessment for other features of sodium channel disease such as sinus node disease, atrial arrhythmias, conduction disease, dilated cardiomyopathy and long QT syndrome (LQT3 subtype) that may coexist with or supplant type 1, 2 or 3 Brugada ECG patterns. Brugada ECG patterns may be present even in sodium channel genotype negative patients. Testing should be carried out in parallel with expert phenotypic assessment, for example in an Inherited Cardiac Clinic (ICC), including support from clinical genetics; testing may occasionally be appropriate outside these criteria following discussion in an ICC MDT.

A firm clinical diagnosis of Brugada syndrome and/or sodium channel disease, as indicated by:
1. Spontaneous type 1 (“coved-type”) ST-segment elevation (characterized by ST-segment elevation ≥2 mm (0.2 mV) in ≥1 right precordial leads (V1–V3) positioned in the 4th, 3rd, or 2nd intercostal space),
OR
2. Type 1 ST-segment elevation unmasked using a sodium channel blocker, AND 1 of the following:
a. Documented VF or polymorphic VT, OR
b. Syncope of probable arrhythmic cause, OR
c. A family history of sudden cardiac death at <45 years old with negative autopsy, OR d. A coved-type ECGs in family members, OR e. Nocturnal agonal respiration OR f. Premature atrial arrhythmias at age <30 years 3. Suspicion of sodium channel disease including atrial arrhythmias, sinus node dysfunction, conduction disease and/or QT prolongation, predominantly in children and young people. NOTE: Clinical evaluation in young probands and cascade testing in families will incorporate assessment for other features of sodium channel disease such as sinus node disease, atrial arrhythmias, conduction disease, dilated cardiomyopathy and long QT syndrome (LQT3 subtype) that may coexist with or supplant type 1, 2 or 3 Brugada ECG patterns. Brugada ECG patterns may be present even in sodium channel genotype negative patients. Testing should be carried out in parallel with expert phenotypic assessment, for example in an Inherited Cardiac Clinic (ICC), including support from clinical genetics; testing may occasionally be appropriate outside these criteria following discussion in an ICC MDT.